NLM Digital Collections

Search

Start Over Languages English ✖Remove constraint Languages: English Publication Year 2020 to 2021 ✖Remove constraint Publication Year: <span class="from" data-blrl-begin="2020">2020</span> to <span class="to" data-blrl-end="2021">2021</span>

151. Health screening for emerging and non-communicable disease burdens among the global poor: evidence from Sub-Saharan Africa

Author(s):
Ciancio, Alberto, author
Kämpfen, Fabrice, author
Kohler, Hans-Peter, author
Kohler, Iliana V., author
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, January 2021
Subject(s):
Developing Countries
Hypertension -- diagnosis
Mass Screening
Africa South of the Sahara
Malawi

155. Patient-focused drug development: collecting comprehensive and representative input : guidance for industry, Food and Drug Administration staff, and other stakeholders

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, June 2020
Subject(s):
Drug Development
Feedback
Sampling Studies
Patient Reported Outcome Measures
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

158. Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia: developing drugs for treatment

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, June 2020
Subject(s):
Drug Development
Healthcare-Associated Pneumonia -- drug therapy
Pneumonia, Bacterial -- drug therapy
Pneumonia, Ventilator-Associated -- drug therapy
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

159. Good manufacturing practice considerations for responding to COVID-19 infection in employees in drug and biological products manufacturing

Publication:
[Silver Spring, MD] : Center for Drug Evaluation and Research, June 2020
Subject(s):
Biological Products
COVID-19 -- prevention & control
Drug Industry
Manufacturing and Industrial Facilities
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

160. Enforcement policy for non-invasive remote monitoring devices used to support patient monitoring during the coronavirus disease 2019 (COVID-19) public health emergency (revised): guidance for industry and Food and Drug Administration staff

Publication:
[Silver Spring, MD] : Center for Drug Evaluation and Research, October 2020
Subject(s):
COVID-19
Monitoring, Physiologic
Remote Sensing Technology
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.